Skip to main content
 Krka
EN
FONT
SIZE
- 0 +
LOWER/UPPERCASE
Lower UPPER
STYLE
Normal Bold
THEME
Reset Close
Slideshow slide
Slideshow slide

LIVING A HEALTHY LIFE

Health is a value and a responsibility we put above everything else.

Krka is one of the leading generic pharmaceutical companies with 70 years of experience. Today, the high quality of our products is recognised all over the world. Our achievements have been built by generations of Krka employees through their courageous and visionary outlook.

Our attitude to people, the environment and the natural heritage as well as our strategic business direction all contribute to a better quality of life.

Movie about Krka

Operating figures are dynamic. The latest operating figures are published in the latest Annual Report.

News

 

Krka received the Best investor relations award
27. 11. 2024

Krka received the Best investor relations award

At the CEE Investment Opportunities conference organised by the Ljubljana and Zagreb Stock Exchanges, Krka won the Best Investor Relations Award of all companies listed on the Ljubljana stock exchange for the fifth time in a row.

 

Investing in knowledge is investing in future success
27. 11. 2024

Investing in knowledge is investing in future success

In 2024, Krka was honoured with the TOP Education Management certificate, placing us among the companies and organisations that invest the most in employee education and development. Krka was awarded the certificate, bestowed as part of the Edutainment conference by Planet GV and Sofos, Institute for Knowledge Management and Talent Development, for the third year in a row.

 

January to September 2024 Business Results
14. 11. 2024

January to September 2024 Business Results

In the nine months of 2024, the Krka Group generated revenue of €1,434.7 million, up 7% year on year, yielding €281 million in net profit, up 19% on the same period last year. The Supervisory Board of Krka discussed the 2024 January to September interim report for the Krka Group and Krka, d. d., Novo mesto at its regular meeting yesterday.
More


Share information

KRKG
-. -. — –:–
Data delayed 15 minutes.
Data source: LJSE.
STABLE DIVIDEND GROWTH STRATEGY

We pursue a long-term strategy of stable dividend growth and allocate at least 50% of net profit of majority shareholders for dividends each year. From 2012 to 2022, the gross dividend per share increased on average by 14.1%.
More 
2021-10-12,308.0455,111
2021-10-13,184.5625,111.5
2021-10-14,391.449,112.5
2021-10-15,367.7925,112
2021-10-18,500.861,112
2021-10-19,272.9405,111.5
2021-10-20,212.74,112.5
2021-10-21,434.2935,112
BECOME PART OF A DEDICATED TEAM

BECOME PART OF A DEDICATED TEAM

Employees are given optimum conditions for development. We quickly recognise their potential, encourage their creativity and value their dedication to work.

More
Slideshow slide 1

Movie about Krka

3:00

Our core business is development, production, marketing and sales of prescription pharmaceuticals, non-prescription products and animal health products.

Operating figures are dynamic. The latest operating figures are published in the latest Annual Report.

Continue browsing

Multiparty banner 1

About us

We are continually consolidating our position as one of the leading generic pharmaceutical companies in the world.

More

Sustainability

We can only consider ourselves successful when our success has a positive impact on the environment and the community.

More

Health matters

Our expert advice is aimed at promoting and raising awareness about the importance of leading a healthy lifestyle.

More